Browse the evidence

Metabolic bariatric surgery is associated with improvements in weight, AHI, upper airway collapsibility, and loop gain.

Practitioners may consider metabolic bariatric surgery as a treatment option for patients with OSA to improve various physiological traits.

82.7% of participants received no further prescriptions for antiobesity medications (AOMs) after their initial prescription.

This indicates a potential gap in ongoing obesity management for these patients.

Tirzepatide is associated with a lower risk of dementia versus SGLT2 inhibitors (HR 0.66, 95% CI 0.47-0.93, p = 0.02).

Tirzepatide may be a preferable treatment option for reducing dementia risk in type 2 diabetes patients compared to SGLT2 inhibitors.

Bariatric surgery achieves 25%–35% total body weight loss with durability extending beyond 10 years.

Bariatric surgery should be considered for long-term weight management in obese patients.

Adjuvant GLP-1RA users achieved a higher mean proportion of days covered (PDC) of 74.30% compared to 66.91% for SGA-only users.

Incorporating GLP-1RA may enhance medication adherence in patients prescribed SGAs.

Adjuvant GLP-1RA users demonstrated longer persistence of 165.6 days compared to 139.2 days for SGA-only users.

GLP-1RA may help patients stay on their SGA medications longer.

Medicaid patients using adjuvant GLP-1RA showed a PDC of 88.25% compared to 70.32% for SGA-only users.

GLP-1RA may significantly improve adherence among Medicaid patients on SGAs.

Key secondary endpoints include categorical weight-loss thresholds, changes in anthropometric and cardiometabolic measures, and comprehensive safety and tolerability assessments.

The trial will assess various health metrics alongside weight loss to evaluate overall impact.

Tirzepatide significantly improved physical function compared with placebo, with a mean difference of 2.26 points in the SF-36 physical function domain.

Practitioners can consider tirzepatide as an effective treatment to enhance physical function in adults with overweight or obesity.

The overall certainty of evidence for the effects of tirzepatide on physical function was rated as moderate due to risk of bias and inconsistency across studies.

Practitioners should be aware of the moderate certainty of evidence when considering tirzepatide for improving physical function.

Tirzepatide increases HOMA-β and decreases HOMA-IR in T2D patients.

Tirzepatide may be effective in improving insulin sensitivity and β-cell function in T2D management.

Global Guidelines for obesity management emphasize the incorporation of novel therapies and integration of standards of care with up-to-date evidence.

Clinicians should adopt these guidelines to improve obesity management globally.

GLP-1-Rezeptoragonisten sollten als Krankenkassenleistung angeboten werden.

Praktiker sollten die Möglichkeit in Betracht ziehen, GLP-1-Rezeptoragonisten in die Krankenkassenleistungen aufzunehmen.

Once-monthly maridebart is associated with HbA1c reductions of approximately 1.2–1.6 percentage points.

Clinicians can anticipate improvements in glycemic control with maridebart therapy.

Among 7,493 members, rates of persistence and adherence to treatment were 60.8% and 60.1%, respectively.

Practitioners should note that adherence to GLP-1 therapies is moderate in this population.

Member-specific factors associated with lower rates of persistence and adherence included male sex, age (<40 years), diabetes, and a lack of weight-related comorbidities.

Understanding these factors can help tailor interventions to improve adherence.

Incretin-based therapies are effective but present limitations for long-term obesity management.

Practitioners should be aware of the limitations of incretin therapies in long-term obesity management.

Obesity without metabolic abnormalities increases the risk of atherosclerotic cardiovascular disease (ASCVD) by 46% in men and 34% in women compared to those with normal BMI.

Practitioners should recognize that obesity, even without metabolic abnormalities, poses significant cardiovascular risks.

Obesity is associated with increased risk of heart failure (HF), with a 63% increase in men and a 69% increase in women compared to those with normal BMI.

Practitioners should be aware of the significant risk of heart failure in obese patients, regardless of metabolic health.

Tirzepatide led to a greater reduction in median triglyceride levels compared with semaglutide.

Tirzepatide may be preferred for patients needing significant triglyceride reduction.

Both groups achieved comparable reductions in body weight after 12 weeks.

Weight loss can be achieved with both dietary interventions during Tirzepatide therapy.

Relative preservation of fat-free mass, muscle strength, and resting metabolic rate was observed in one dietary context.

Choosing the right dietary context may help preserve muscle and metabolic health during weight loss.

Short-term changes in glycaemic parameters were statistically associated with concurrent changes in fat-free mass, muscle strength, and resting metabolic rate.

Monitoring glycaemic parameters may provide insights into metabolic health during weight loss.

Discontinuation of GLP-1 receptor agonists is associated with substantial weight regain of 60%-90% within one year.

Clinicians should anticipate significant weight regain in patients discontinuing GLP-1RA therapy.